期刊文献+

临床药师参与1例肥胖患儿颅内曲霉菌感染的药物治疗

Drug Therapy Analysis of Clinical Pharmacist Participating in a Case of Intracranial Aspergillus Infection
下载PDF
导出
摘要 目的:探讨儿科临床药师在肥胖患儿颅内曲霉菌感染治疗中的作用。方法:临床药师通过参与1例肥胖患儿颅内曲霉菌感染的药物治疗实践,调整肥胖患儿用药方案,监测抗真菌药物血药浓度、检测代谢基因并调整剂量,降低了药物不良反应发生率。结果:经过1个月抗感染治疗,患儿病情好转出院。结论:对于罕见颅内曲霉菌感染肥胖患儿,临床药师进行了个体化药物治疗,保障了儿童用药的安全性和有效性。 Objective:To explore the role of clinical pharmacists in the treatment of intracranial Aspergillus infection in obese children.Methods:Clinical pharmacists participated in the drug therapy of intracranial Aspergillus infection in an obese child,recommended the initial dose of the obese child,monitored the blood concentration of voriconazole,detected metabolic genes and adjusted the dose,which reduced the incidence of adverse drug reactions related to voriconazole. Results: After 1 month of anti-infection treatment, the child wasdischarged from hospital with improved condition. Conclusion: For rare intracranial Aspergillus infection, clinical pharmacists shouldcarry out individualized drug therapy for obese children to ensure the medication safety and effectiveness for children.
作者 何丹 曹清 蒋樾廉 张顺国 He Dan;Cao Qing;Jiang Yuelian;Zhang Shunguo(Shanghai Children’s Medical Center,School of Medicine,Shanghai Jiaotong University,Shanghai 200127,China)
出处 《儿科药学杂志》 CAS 2023年第4期13-17,共5页 Journal of Pediatric Pharmacy
关键词 临床药师 儿童 肥胖 曲霉菌 clinical pharmacist children obesity Aspergillus
  • 相关文献

参考文献4

二级参考文献38

  • 1李辉,朱宗涵,张德英.2005年中国九市七岁以下儿童体格发育调查[J].中华儿科杂志,2007,45(8):609-614. 被引量:217
  • 2Bellizzi MC, Dietz WH. Workshop on childhood obesity: summary of the discussion. Am J Clin Nutr,1999,70∶s173-s175.
  • 3Zhou BF. Predictive values of body mass index and waist circumfer-ence for risk factors of certain related disease in Chinese adults-study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomedical and Environ ment
  • 4Cole TJ, Bellizzi MC, Flegal KM, et al. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ, 2000, 320∶1240-1243.
  • 5Malina RM, Katzmarzyk PT. Validity of the body mass index as an indicator of the risk and presencr of overweight in adolescents. Am J Clin Nutr,1999,70∶131-136.
  • 6Flegal KM, Carrol MD, Kuczmarski RJ, et al.Overweight and obesity in the United States: Prevalence and trends.Int J Obes,1998,22∶39-47.
  • 7He Q, Albertsson-Wikland K,Karlberg J.Population-based body mass index reference values from Goteborg Sweden: birth to 18 years of age. Acta Paediatr,2000,89∶582-592.
  • 8Deniels SR, Khoury PR, Morrison JA.The utility of body mass index as a measure of body fatness in childhood and adolescents: differences by race and gender.Pediatrics,1997,99∶804-807.
  • 9WHO. Obesity: preventing and managing. The global epidemic. Report of a WHO consultation on obesity. Technical Report Series,Geneva,WHO,2000,894∶83.
  • 10日本肥满学会肥满症诊断基准检讨委员会.肥满筛查和肥满症诊断新基准[J].(日)肥满研究,2000,6:18-28.

共引文献2519

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部